Hutchinson-Gilford Progeria syndrome 早年衰老症候群

Hutchinson-Gilford Progeria syndrome
繁：早年衰老症候群
简：早年衰老症候群

生命意義不在乎長短，美國一名女童出生後不久確診罕見病「早年衰老症候群」（簡稱早衰症），醫生曾斷言該名女童活不過13歲，女童現已活至11歲，她的外表與一般小童有異，由於皮膚緊皺而貌似老人，成長至今飽受冷眼歧視，甚至曾有陌生人譏笑她像外星人。

患早衰症貌似老人被譏外星人　11歲女童笑對死亡：我有自己使命（2018年9月12日）。經濟日報，取自 https://topick.hket.com/article/2159327/%E6%82%A3%E6%97%A9%E8%A1%B0%E7%97%87%E8%B2%8C%E4%BC%BC%E8%80%81%E4%BA%BA%E8%A2%AB%E8%AD%8F%E5%A4%96%E6%98%9F%E4%BA%BA%E3%80%8011%E6%AD%B2%E5%A5%B3%E7%AB%A5%E7%AC%91%E5%B0%8D%E6%AD%BB%E4%BA%A1%EF%BC%9A%E6%88%91%E6%9C%89%E8%87%AA%E5%B7%B1%E4%BD%BF%E5%91%BD%E3%80%80

Eiger BioPharmaceuticals has secured the Rare Pediatric Disease (RPD) designation from the US Food and Drug Administration (FDA) for lonafarnib to treat both Hutchinson-Gilford Progeria Syndrome (HGPS or progeria) and progeroid laminopathies.

Eiger’s lonafarnib secures RPD designation from FDA to treat Progeria. (2018, October 23). The Pharma Letter. Retrieved from https://www.pharmaceutical-business-review.com/news/eigers-lonafarnib-secures-rpd-designation-from-fda-to-treat-progeria/